Precision Immuno-Oncology Market to grow with a CAGR of 9.90%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Precision Immuno-Oncology Market.
According
to TechSci Research report, “Global Precision Immuno-Oncology Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Precision
Immuno-Oncology Market has valued at USD 51.20 billion in 2022 and is anticipated
to witness an impressive growth in the forecast period with a CAGR of 9.90%
through 2028. This can be due to collaborations and partnerships among leading
companies with a diverse approach to merge the expertise of individual
companies and to strengthen their position in the market. Genomic and molecular
profiling drive the demand for Precision Immuno-Oncology. Genomic and molecular
profiling techniques, such as next-generation sequencing (NGS), help identify
specific genetic mutations and alterations within a patient's tumor. This information
is crucial for determining whether the tumor has targetable mutations that may
respond to precision immuno-oncology treatments. Profiling can predict a
patient's likelihood of responding to immunotherapy. For example, the presence
of high tumor mutational burden (TMB) or specific genetic markers may indicate
a better response to immune checkpoint inhibitors. Profiling helps identify
potential synergies between different types of therapies. By understanding the
genetic and molecular characteristics of a tumor, clinicians can determine
which combinations of treatments, such as immunotherapy with targeted therapy
or radiation therapy, are most likely to be effective. Genomic and molecular
profiling can match patients with clinical trials testing specific precision
immuno-oncology therapies. This accelerates the development of new treatments
and expands treatment options for patients. Molecular profiling techniques,
including liquid biopsies, enable the ongoing monitoring of a patient's
response to treatment. This allows for timely modifications to the treatment
plan if resistance or disease progression is detected.
Precision Immuno-Oncology aims to minimize
overtreatment by avoiding therapies that are unlikely to be effective. This
reduces unnecessary side effects and improves the patient's quality of life. Throughout
treatment, patients' responses are closely monitored. If resistance develops or
disease progression occurs, treatment plans can be adapted and modified based
on ongoing genomic and immune profiling.
In August 2022, Ipsen and Marengo Therapeutics, Inc.
have joined forces in a strategic partnership aimed at progressing two
preclinical candidates generated through Marengo's STAR platform into clinical
trials. This collaboration will harness Marengo's exclusive research and
development capabilities, focusing on a novel T cell activation mechanism,
while leveraging Ipsen's worldwide presence in the field of oncology for the
clinical development and eventual commercialization of these candidates.
Marengo's Selective T Cell Activation Repertoire (STAR) platform comprises a
library of multi-specific fusion proteins that target distinct TCR Vβ variants,
combined with various co-stimulatory elements to create potent T cell
activators. What sets this platform apart is its ability to precisely modulate
the T cell response within specific T cell subsets, resulting in the generation
of natural, highly effective T cells capable of eliminating solid tumor cells.
Limited
patient eligibility is a challenge in the Global Precision Immuno-Oncology
Market. This challenge arises due to several factors that restrict the number
of patients who can benefit from precision immuno-oncology approaches. Precision
immuno-oncology often relies on specific biomarkers, such as PD-L1 expression,
tumor mutational burden (TMB), or specific genetic mutations. Patients who do
not have the relevant biomarkers may not be eligible for certain targeted or
immunotherapeutic treatments. Tumor heterogeneity, where different regions of
the same tumor have distinct genetic profiles, can complicate biomarker
assessment. In some cases, a biopsy from one region may not accurately
represent the entire tumor, potentially leading to inaccurate eligibility
assessments. Some biomarkers are relatively rare, meaning that only a small
subset of patients with a particular cancer type will have them. This rarity
limits the number of eligible patients for targeted therapies or clinical
trials.
Browse
over XX market data Figures and spread through XX Pages and an in-depth TOC on
" Precision Immuno-Oncology Market.”
Global Precision Immuno-Oncology Market is
segmented based on Cancer Type, Treatment Type, Biomarker, End User, and by
region.
Based on Biomarker,
Global Precision Immuno-Oncology Market is segmented into PD-L1, BRCA, KRAS,
EGFR, and others. The EGFR (Epidermal Growth Factor Receptor) biomarker
is a protein found on the surface of some cells, including certain cancer
cells. It plays a significant role in cell growth and division, and alterations
in the EGFR gene and protein can have implications in cancer diagnosis and
treatment. Mutations or overexpression of EGFR can lead to uncontrolled cell
growth and division, a hallmark of cancer. Alterations in the EGFR gene are
commonly found in several types of cancer, including lung cancer, colorectal
cancer, and certain types of brain tumors. These alterations can result in the
continuous activation of EGFR signaling, contributing to cancer development and
progression. EGFR is used as a diagnostic biomarker in cancer. Genetic testing
can identify mutations or alterations in the EGFR gene or overexpression of the
EGFR protein. Detection of these alterations helps oncologists classify tumors,
predict their behavior, and guide treatment decisions.
Based on Region, North America dominated the Global Precision Immuno-Oncology Market. The
region has extensive healthcare databases and patient data repositories, which
are crucial for the development of personalized treatment approaches in
immuno-oncology. North America tends to be an early adopter of innovative
medical technologies and therapies. Physicians in the region are often open to
integrating new treatments into clinical practice. Many of the world's largest
pharmaceutical companies are headquartered in North America, enabling them to
influence and lead developments in precision immuno-oncology on a global scale.
Patient demand for cutting-edge cancer treatments is high in North America.
Patients often seek access to the latest therapies and are willing to
participate in clinical trials.
Some
of the major companies operating in the Global
Precision Immuno-Oncology Market include:
- Adaptimmune
Therapeutics Plc
- Agenus
Inc.
- Amgen
Inc
- AstraZeneca
plc
- Bristol
Myers Squibb Company
- Celgene
Corporation
- Eli
Lilly and Company
- F.
Hoffmann-La Roche Ltd.
- Gilead
Sciences, Inc
- GlaxoSmithKline
Plc
Download Free Sample Report
Customers can also request 10% free
customization on this report.
“Certain areas, particularly in North
America, are projected to exert significant demand for precision immune
oncology. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Precision Immuno-Oncology Market in the forecast period,"
said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Precision Immuno-Oncology Market By Cancer type (Lung cancer, Breast cancer,
Prostate cancer, Melanoma, and others), By Treatment type (Checkpoint
Inhibitors, Car T cell Therapy, Cancer Vaccines, and others), By Biomarker
(PD-L1, BRCA, KRAS, EGFR, and others), By End-user (Hospital & Clinics,
Research Institutes, others), By
Region, By Competition Forecast
& Opportunities, 2018-2028F has
evaluated the future growth potential of Global Precision Immuno-Oncology Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Precision Immuno-Oncology Market.
Contact
Mr.
Ken Mathews
Techsci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States-
10170
Tel:
+13322586602
Email: [email protected]
Website: www.techsciresearch.com